Inarktika will pay dividends for the first half of the year for 878.7 million rubles

253
2
AK&M 25 September 2026 11:28

Inarktika will pay dividends for the first half of 2026 in the amount of 878.766 million rubles. This is stated in the company's message.

10 rubles were accrued per share. The dividends must be paid by October 16, 2026.

It should be recalled that Inarktika paid dividends for 2025 for 878.766 million rubles.

"Russian"Russian Sea Group" PJSC Inarktika (TIN 7816430057; formerly PJSC "Russian Aquaculture", until February 18, 2015 — "Russian Sea" group of companies) is the group's management company operating in the segment of Atlantic salmon and trout production in Russia.

The key activities of the group under the company's management include: commercial cultivation of Atlantic salmon and sea trout in the Barents Sea in the Murmansk region; commercial cultivation of trout in the lakes of the Republic of Karelia.

The authorized capital as of December 31, 2025 is 8.787 billion rubles (87.87 million shares with a nominal value of 100 rubles). The company has no beneficial owner as of December 31, 2025, as well as shareholders holding more than 25% of shares.

The company's revenue under RAS for 2025 fell by 72.7% to 1.4 billion rubles, net profit — by 76.9% to 1.13 billion rubles.

PJSC "Inarktika"'s net loss under IFRS for 2025 amounted to 2.2 billion rubles, taking into account the impact of the revaluation of biological assets. A year earlier, net profit amounted to 7.8 billion rubles. Adjusted net profit fell by 79% to RUB 2.1 billion from RUB 10.3 billion. Adjusted EBITDA amounted to 5.7 billion rubles, a decrease of 54%.

The net loss of Inarktics, taking into account the revaluation of biological assets under IFRS for the first half of 2026, amounted to 0.4 billion rubles against a loss of 7.5 billion rubles a year earlier. Adjusted net profit excluding the revaluation of biological assets increased twofold to 1.6 billion rubles from 0.8 billion rubles. Revenue increased by 38% to 13.8 billion rubles from 8.4 billion rubles. Gross profit before revaluation of biological assets increased by 19% to 4.5 billion rubles from 3.8 billion rubles. Adjusted EBITDA increased by 38% to 3.4 billion rubles from 2.5 billion rubles.